Frontlight ResearchEarly access
Sickle cell disease trials in Israel
2 of 3 trials · From ClinicalTrials.gov, checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 4Enrolling by invitationA Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study
- Where
- Haifa, Safed
- Age
- 18 years and over
- People
- 55 worldwide
- Run by
- Agios Pharmaceuticals, Inc.
See details and how to joinNCT05777993 · EU 2026-526243-35-00 - Phase 3Taking peopleThe Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
- Where
- Afula, Haifa
- Age
- 10 years to 65 years
- People
- 192 worldwide
- Run by
- Sanofi
See details and how to joinNCT06975865